Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD2-396 hepatitis B combination vaccine in infants
jRCT2031230390Completed
- Sponsor
- KM Biologics
- Start
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, single-blind trial of KD2-396 in pertussis, diphtheria, Tetanus and 3 more (3 arms), sponsored by KM Biologics. Primary endpoints: Primary immunogenicity for bacterial toxoids and pertussis antigens at Visit 4, Primary immunogenicity for poliovirus at Visit 4 and 1 more. Started Oct 2023; status: completed.
02
Drugs
KD2-396
03
Conditions
pertussisdiphtheriaTetanuspoliomyelitisHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on jRCT2031230390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230390.